HER2 has emerged as a significant biomarker in UC, holding considerable therapeutic implications. Given the tumor-agnostic approval of T-DXd for patients with HER2 IHC 3+ expression, all patients with ...
Beyond a cancer cell’s genetic blueprint, the expression levels of certain proteins on its surface is emerging as a collection of critical, actionable biomarkers. Instead of looking for a mutated gene ...
CASI-01 is the first international study to apply IHC calibration (using IHCalibrators (R) from Boston Cell Standards) to evaluate HER2 testing across multiple laboratories. Results showed that ...
Prophylactic Radiation Therapy Versus Standard of Care for Patients With High-Risk Asymptomatic Bone Metastases: A Multicenter, Randomized Phase II Clinical Trial This open-label phase II study ...
Researchers from Lund University (Sweden) have investigated the tumor immune microenvironment of primary triple-negative breast cancer using digital image analysis of IHC-stained immune cells. To do ...
The FDA granted tumor-agnostic accelerated approval to trastuzumab deruxtecan (Enhertu) for previously treated unresectable or metastatic HER2-positive (immunohistochemistry [IHC] 3+) solid cancers.
—Adopting evidence-based, unified scoring criteria specifically validated for colorectal cancer could help ensure that the right patients receive the right targeted treatment at the right time. Human ...
BOSTON--(BUSINESS WIRE)--Foundation Medicine, Inc., a genomics company committed to transforming cancer care, today announced that it has expanded its immunohistochemistry (IHC) test offerings to ...
Michael Hassett, MD, explains the evolving landscape of HER2-positive breast cancer treatment and the role of CDK inhibition ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback